Skip to main content

Featured

Tariff Costs Put New Pressure on U.S. Corporate Profits

Rising tariff expenses are beginning to weigh heavily on U.S. companies, prompting executives across multiple industries to warn that profit margins may tighten in the months ahead. Many firms had initially suggested they could manage the added costs through efficiency improvements or selective price increases, but that confidence is fading as import-related expenses continue to climb. Companies that rely on global supply chains are feeling the strain most acutely. Higher costs on imported materials and components are forcing difficult decisions: pass the increases on to consumers, risking weaker demand, or absorb the costs internally, which directly erodes profitability. For many businesses, neither option is attractive. Consumer-facing brands are finding it especially challenging to raise prices further, as shoppers show growing sensitivity to even modest increases. This resistance limits the ability of firms to offset tariff-driven expenses, creating a squeeze that is beginning t...

article

Health Canada authorizes updated Pfizer-BioNTech COVID vaccine


Health Canada has authorized Pfizer-BioNTech’s updated COVID-19 vaccine for people six months and older.

The mRNA vaccine targets the Omicron XBB.1.5 subvariant that is circulating in Canada.

This is the second vaccine targeting XBB.1.5 that will be available in this country.

Earlier this month, Health Canada authorized Moderna's updated mRNA vaccine.

Both Pfizer and Moderna's shots are one-dose vaccines for people five years of age and older.

Three shots of the Pfizer vaccine is recommended for children between six months and four years of age who have not received their primary series of a COVID-19 vaccine.

Health Canada says it is currently reviewing an updated non-mRNA vaccine from Novavax.

Novavax’s vaccine has been submitted for consideration for people age 12 years and older.

Comments